Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Hot brew coffee has more antioxidant capacity than cold brew, finds study

In a new study, Jefferson researchers found chemical differences between hot and cold brew coffee that may have health impacts.

1 Nov 2018

Survey: Strong bipartisan support for public health

At the launch of the autumn flu season and amid a rash of weather-related disasters affecting many states, nine in 10 registered voters (89%) believe public health departments play an important role in the health of their community, according to a new poll released today by the de Beaumont Foundation.

30 Oct 2018

Scientists discover cell adhesion mechanism used by mycoplasma genitalium

Researchers from the Molecular Biology Institute of Barcelona and the Institute of Biotechnology and Biomedicine have discovered the mechanism by which the bacterium Mycoplasma genitalium) adheres to human cells.

29 Oct 2018

Study provides a new way of thinking about cold stress in plants

When temperatures drop, plants can't bundle up. Stuck outside, exposed, plants instead undergo a series of biochemical changes that protect cells from damage.

29 Oct 2018

Researchers propose new contactless method for measuring blood flow in the upper limbs

The research team from Russia proposed a new contactless method for measuring blood flow in the upper limbs. The method is based on video recording of the skin surface under green light measuring the absorption of red blood cells. This helps to see how effective the circulatory system and the blood flow regulation are.

29 Oct 2018

Getting right level of leptin may help protect cardiovascular health

Like that famous bowl of porridge, when leptin levels are "just right" they help protect our cardiovascular health, scientists say.

29 Oct 2018

Turning tumor-promoting fibroblasts against pancreatic cancer

Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer's growth. Even with treatment, most patients live only about six months after they are diagnosed with the disease.

26 Oct 2018

Molecular breakthrough may improve prognosis for pancreatic cancer

Scientists have discovered a method by which fibroblasts in the stroma of pancreatic tumors can be reprogrammed to suppress tumor cell growth.

26 Oct 2018

Influenza virus can evolve resistance to experimental antiviral drug

The influenza virus can evolve resistance to an anti-flu drug currently in development for use in pandemics but only if there are multiple genetic mutations, a study has found.

25 Oct 2018

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

A new drug that works against flu has been developed and has been approved by the Food and Drug Administration (FDA) yesterday (24th October 2018). Until now the only drug available for flu is oseltamivir (Tamiflu) which is to be administered by two pills per day for five days after symptoms appear.

25 Oct 2018

Battling against resistant and sensitive types of influenza A

Another flu season is here, which means another chance for viruses to mutate. Already, most influenza A viruses contain a mutation that confers resistance against one class of antiviral medications, and the bugs are steadily gaining resistance against another class.

25 Oct 2018

FDA approves new antiviral flu treatment

Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

24 Oct 2018

High-dose influenza vaccine associated fewer hospitalizations in dialysis patients

Results from a new study suggest that high-dose influenza vaccine is associated with lower risk for hospitalizations in kidney failure patients on dialysis. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology

24 Oct 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

Research suggests new approach to protect from common cold

As temperatures drop and the sniffles start, take hope; research published this summer suggests a new approach to protect ourselves from the common cold.

24 Oct 2018

Temperature increases in Zambezi Valley may cause major declines in tsetse populations

A new study, based on 27 years of data from Mana Pools National Park in Zimbabwe, suggests that temperature increases over the last three decades have already caused major declines in local populations of tsetse flies.

24 Oct 2018

How to avoid shoulder injury related to vaccine administration

A study by researchers at the University of Waterloo reiterates the need for health care professionals, including pharmacists, to take certain precautions to minimize the risk of their patients suffering shoulder injury related to vaccine administration

24 Oct 2018

Impact of climate change on sleeping sickness vector population in Africa

LSTM's Dr Jennifer Lord is first author on a paper looking at the impact of climate change on the vectors of sleeping sickness in Africa.

23 Oct 2018

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

23 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018